THE PREVALENCE OF CYP2C19*2, *3 POLYMORPHISMS AMONG RUSSIANS AND YAKUTS WITH PEPTIC ULCER DISEASE, LIVING IN SAKHA REPUBLIC (YAKUTIA)

DOI: https://doi.org/10.29296/24999490-2018-04-06

I.I. Temirbulatov(1, 2), D.V. Ivashchenko(1), Z.A. Rudykh(3), N.V. Popova(3), K.S. Tayurskaya(3), Ya.V. Chertovskikh(4), D.A. Sychev(1) 1-Russian Medical Academy of Continuous Professional Education, Barrikadnaya str., 2/1, Moscow, 125993, Russian Federation; 2-I.M. Sechenov First Moscow State Medical University, Trubetskaya street, 8, Moscow, 119991, Russian Federation; 3-Centre of Personalized Medicine of Republic Hospital №3, Kirova str., 34, Yakutsk, 677027, Russian Federation; 4-Ministry of Healthcareof the Sakha Republic (Yakutia), Lenina str., 30, Yakutsk, 677011, Russian Federation E-mail: [email protected]

Introduction. Proton pump inhibitors (PPI) are widely spread as antisecretory drugs for a treatment of acid diseases, such as the gastric ulcer. Most of the proton pump inhibitors are inactivated in the liver by cytochromes P450 2C19 (CYP2C19) to the form of inactive metabolites. Gene polymorphisms CYP2C19 can influence the speed of the inactivation of drugs, and can also influence a clinical response to the PPI drugs therapy. The aim. To compare the frequency of the occurrence of polymorphic variants of the gene CYP2C19*2 and *3 among Russians and Yakutssuffered from the gastric ulcer residing in the Republic of Sakha. Methods. The study included 204 gastric ulcer patients from the Republic of Sakha(including 63 Russian people and 141 Yakuts). 10 ml of the venous blood was taken from each patient. Polymorphisms CYP2C19*2 and CYP2C19*3 were determinedby the method of the polymerase chain reaction in the real time. Results. In the total sample (n=204), the CYP2C19*1/*1 was determined in 122 patients (59,8%), the CYP2C19 *1/*2 –50 (24,5%), the CYP2C19 *1/*3 – 24 (11,8%), and the CYP2C19 *2/*3 in 8 patients (3,9%). 37 (58,7%) Russian patients (n=63) were the CYP2C19*1/*1 carriers, 16 patients (25,4%) were the *1/*2 carriers, 9 patients (14,3%) were the *1/*3 carriers, and 1 patient (1,6%) had a *2/*3 genotype. The genotype prevalence in Yakuts was distributed as follows: *1/*1- 85 (59,8%), *1/*2 – 34 (24,1%), *1/*3 15 (10,6%), *2/*3-7 (5%). We did not found significant gender (p=0,944) and nationality (p=0,614) differences in the frequency of polymorphisms. Conclusions. We found no significant differences in the frequency of polymorphisms CYP2C19*2 and *3 in Russians and the Yakuts, residents of the Republic of Sakha. To make the final conclusions of the presence of ethnic features while PPI prescribing, the determination of a frequency of occurrence CYP2C19*17 alleles among these nations has to be made.
Keywords: 
pharmacogenetics, ethnopharmacogenetics, CYP2C19, proton pump inhibitors, Yakutia
Список литературы: 
  1. Shi S. and Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 2008; 64 (10): 935–51.
  2. Mullin J.M., Gabello M., Murray L.J., Farrell C.P., Bellows J., Wolov K.R., Kearney K.R., Rudolph D., Thornton J.J. Proton pump inhibitors: actions and reactions. Drug Discov. Today. 2009; 14 (13 14): 647 60.
  3. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 2006; 44 (7): 297–302.
  4. Hagymási K., Müllner K., Herszényi L., and Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011; 12 (6): 873–88.
  5. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 2006; 79 (1): 103–13.
  6. Esplugues J.V., Marti-Cabrera M., Ponce J. Safety of proton pump inhibitors. Med. Clin. (Barc). 2006; 127 (20): 790 5.
  7. Neha Deshpande, Sharanya V., Ravi Kanth V.V., Murthy H.V. V., Sasikala M., Rupa Banerjee, Manu Tandan, and Nageshwar Reddy D. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta gene. 2016; 9: 159 64.
  8. Chao-Hung Kuo, Chien-Yu Lu, Hsiang-Yao Shih, Chung-Jung Liu, Meng-Chieh Wu, Huang-Ming Hu, Wen-Hung Hsu, Fang-Jung Yu, Deng-Chyang Wu, and Fu-Chen Kuo. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J. Gastroenterol. 2014; 20 (43): 16029–36.
  9. Baldwin R.M., Ohlsson S., Pedersen R.S., Mwinyi J., Ingelman-Sundberg M., Eliasson E., Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. 2008; 65 (5): 767–74.
  10. Fricke-Galindo I., Céspedes-Garro C., Rodrigues-Soares F., Naranjo M.E., Delgado Á., de Andrés F., López-López M., Peñas-Lledó E., LLerena A. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and «measured» metabolic phenotypes across world populations. Pharmacogenomics J. 2016; 16 (2): 113–23.
  11. Mirzaev K.B., Zelenskaya E.M., Barbarash O.L., Ganyukov V.I., Apartsin K.A., Saraeva N.O., Nikolaev K.Y., Ryzhikova K.A., Lifshits G.I., Sychev D.A. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics. Pers. Med., 2017; 10: 107–14.
  12. Kantemirova B.I., Griganov V.I., Dubina D.Sh., Alieva Z.G. Polimorfizm gena CYP2C19 u detey, prozhivayushhih v Astrahanskom regione. Medicinskiy vestnik Bashkortostana. 2012; 4: 29–31. [Kantemirova B.I., Griganov V.I., Dubina D.SH., Alieva Z.G. Polimorfizm gena CYP2C19 u detej, prozhivayushchih v Astrahanskom regione. Medicinskij vestnik Bashkortostana. 2012; 4: 29–31 (in Russian)]
  13. Carukyan A.A. Baturin V.A. Geneticheskiy polimorfizm izofermentov citohroma CYP2C9 v e`tnicheskih gruppah naseleniya Stavropol`skogo kraya. Kubanskiy nauchnyy medicinskiy vestnik. 2012; 4: 181–3. [Carukyan A.A. Baturin V.A. Geneticheskij polimorfizm izofermentov citohroma CYP2C9 v ehtnicheskih gruppah naseleniya Stavropol’skogo kraya. Kubanskij nauchnyj medicinskij vestnik. 2012; 4: 181–3 (in Russian)]
  14. Chertovskikh Y.V., Malova E.U., Maksimova N.R., Popova N.V., Sychev D.A. VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts). Int. J. Risk Saf. Med. 2015; 27 (s1): 17–8.
  15. Vasilyev F.F., Danilova D.A., Kaimonov V.S., Chertovskih Y.V., Maksimova N.R. Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population. Res. Pharm. Sci. 2016; 11 (3): 259 64.
  16. Sychev D.A., Shuev G.N., Suleymanov S.S., Ryzhikova K.A., Mirzaev K.B., Grishina E.A., Snalina N.E., Sozaeva Z.A., Grabuzdov A.M., Matsneva I.A. Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmgenomics. Pers. Med. 2017; 10: 93–9.
  17. Denisenko N., Sychev D., Sizova Z., Grachev A., Velikolug K. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics. Pers. Med. 2015; 8: 111.
  18. Rhanderson N. Cardoso, Alexandre M. Benjo, James J. Di Nicolantonio, Daniel C. Garcia1, Francisco Y.B. Macedo, Georges El-Hayek, Girish N. Nadkarni, Sebastiano Gili, Mario Iannaccone, Ioannis Konstantinidis6 and John P. Reilly. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Hear. 2015; 2 (1): e000248.
  19. Scott S.A., Sangkuhl K., Stein C.M., Hulot J.S., Mega J.L., Roden D.M., Klein T.E., Sabatine M.S., Johnson J.A., Shuldiner A.R. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 2013; 94 (3): 317–23.
  20. Mega J.L., Simon T., Collet J.P., Anderson J.L., Antman E.M., Bliden K., Cannon C.P., Danchin N., Giusti B., Gurbel P., Horne B.D., Hulot J.S., Kastrati A., Montalescot G., Neumann F.J., Shen L., Sibbing D., Steg P.G., Trenk D., Wiviott S.D., Sabatine M.S. Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA. 2010; 304 (16): 1821.